Madison biotech firm partners to expand its therapeutics research

Nimble Therapeutics, a Madison-based biotechnology company that uses a peptide discovery platform to identify medicines for challenging-to-drug targets, is expanding its collaboration with Genentech, a member of the Roche Group, for the discovery of peptide therapies for the treatment of diseases across multiple therapeutic areas.

Under the terms of the agreement, Nimble will receive a $20 million upfront payment; near-term, preclinical, clinical, and commercial milestone payments that could exceed $1.1 billion; as well as tiered royalties. Nimble will apply its platform against multiple targets, and Genentech and Roche will be responsible for preclinical and clinical development, and commercialization of any resulting products.